SBIR/STTR Research Award
An Isotonic Biome-Friendly Vaginal Moisturizer to Relieve Genitourinary Menopausal Symptoms
Award amount
$149,922Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- FAIRHAVEN HEALTH, L.L.C.
- Proposal award date
- 2018-09-01
- Contract end date
- 2019-02-28
- UEI
- Not reported
- Solicitation number
- PA17-302
- Topic code
- NICHD
Research abstract
An Isotonic Biome Friendly Vaginal Moisturizer to Relieve Genitourinary Menopausal Symptoms
SUMMARYPostmenopausalPMwomen suffer from vaginal atrophywith a loss of natural moisture and elasticityas well as vaginal dysbiosis and increased vaginal pHcollectively known as the Genitourinary Syndrome of
MenopauseGSMSymptoms of GSM include vaginal drynessburningirritation and malodoras well as sexual
dysfunctionThere aremillion such women in the US and overof these women have signs of GSM at
menopauseSymptoms progress over time and require continual treatmentCurrent vaginal lubricants and
moisturizersVLandamp Mare first line therapies for GSM but they can cause vaginal mucosal damage and inhibit healthy
lactobacillus growthbased on physiochemical properties and formula excipientsThere is an unmet need for a
VLandamp M that relieves symptoms of GSM while minimizing disruption to the vaginal ecosystemThe overall goal of
this proposal is to develop a biome friendlymoisturizinglubricating and pH balancing vaginal gel for
improved GSM symptom relief in PM womenFairhaven Health specializes in womenandapos s healthincluding an
isotonic vaginal product lineA VLandamp M gel prototype has been developedSAGEto improve GSM symptom relief
by reducing immunemucosaland biome toxicitycompared to existing productsSAGEandapos s proprietary formula has
been preliminarily found to cause less mucosal irritation and less disruption to healthy lactobacillus versus existing
VLandamp MA novel unit dose applicator system has been designed to deliver the sterilepreservative free SAGEThe
following PhaseAims will move SAGE towards commercializationAimFinalize Formula andampCompare
Functional PropertiesAStudies will define the final SAGE formula and mixing protocols to ensure
physiochemical properties are retained during sterilization and stability testingBStudies will confirm key
functional propertiesfor GSM symptom reliefof mucoadhesionlubricity and buffering capacity of SAGE versus
competitive productsAimVaginal Biome Compatibility Testing Evaluation of SAGE in this Aim will be
performed by the Laboratory of Genital Tract Biology at Brigham and Womenandapos s HospitalAStudies will evaluate
the impact of SAGE and competitive products on valuable vaginal Lactobacillus species of the healthy human
vaginaBA human in vitro model study will monitor markers of cell damage and immunotoxicity following contact
of bacteria colonized vaginal epithelia with SAGE versus competitive VLandamp MA final SAGE formula will be
acceptable for a PhaseSBIR if it is equivalent or superior to other VLandamp M in functional propertiesand superior
over competitors in epithelium associated lactobacillus colony forming unitsepithelial integrityand or markers of
epithelial disruption and inflammatory activityThe team behind SAGE has combined expertise in clinical and
experimental vaginal biologyvaginal product developmentregulatory clearancesterile manufacturing of
gels and commercial sales in womenandapos s vaginal products An Isotonic Biome Friendly Vaginal Moisturizer to Relieve Genitourinary Menopausal Symptoms
NARRATIVE
Postmenopausal women suffer from vaginal atrophywith a loss of natural moisture and elasticityas well as a rise
in vaginal pHcausing the Genitourinary Syndrome of MenopauseGSMwith symptoms of vaginal drynessburningirritation and malodoras well as sexual dysfunctionCurrent vaginal lubricants and moisturizersVLandamp Mare first line therapies for GSM but they can cause vaginal mucosal damage and harm healthy lactobacillusbased
on their formulas and chemistryThe goal of this proposal is to develop a biome friendlymoisturizinglubricating and pH balancing vaginal gel for improved GSM symptom reliefusing a state of the art human invitro model to evaluate markers of cell damage and immunotoxicityas well as lactobacillus growth for the new gel
versus existing VLandamp M
Technology keywords
Not reported